A new study found that patients with type 2 diabetes receiving glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors (SGLT2i), had a lower risk of developing Alzheimer's disease and related dementias compared with other glucose-lowering drugs. "We found about 33% to 43% lower risk," said senior study author Jingchuan Guo, MD.

Source: JAMA Neurology